RECEPTOR.AI
Receptor.AI is a TechBio company offering an AI-native multiplatform drug discovery ecosystem spanning small molecules, peptides, and induced proximity modalities. It serves pharmaceutical, biotechnology, and academic clients globally through project-based services and SaaS access, supported by proprietary QuorumMap, ArtiDock, and ADMETiQ AI models.
- Company typePrivate
- Founded2021
- HeadquartersCambridge, United States
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What RECEPTOR.AI does
Receptor.AI is a TechBio company providing AI-accelerated preclinical drug discovery services through a multiplatform ecosystem spanning three modality-specific platforms: Small Molecules, Peptides, and Biologics & Proximity Inducers. Founded in Q1 2021 in Kyiv and now headquartered in London with a US headquarters in Cambridge, MA and an R&D facility in Magdeburg, Germany, the company targets pharmaceutical companies (including Top-5 Big Pharma), mid-sized pharma/biotech firms, and academic institutions across North America, Europe, and Asia. Core proprietary technologies include QuorumMap (a multi-objective navigation engine exploring 10^16-scale chemical space), ArtiDock (an AI docking model claimed to outperform AlphaFold), ADMETiQ (predictive evaluation across 80+ ADMET endpoints), StratAI Decision Engine (autonomous project-level orchestration driven by experimental feedback), and AI Pocket Detection for identifying allosteric, cryptic, transient, and hidden binding pockets. The platforms are integrated with specialized experimental laboratories enabling end-to-end drug candidate design from hit identification through lead optimization and preclinical candidate selection.
The company operates a dual revenue model combining project-based collaborative drug discovery services (professional services spanning hit identification, hit-to-lead, lead optimization, and preclinical candidate selection) and a recurring SaaS/platform licensing layer for technology access. Its go-to-market is sales-led and enterprise-focused, with direct engagement via "Request a Demo" CTAs and a dedicated BDR team targeting pharma and biotech partners worldwide. Disclosed commercial traction includes 40+ completed drug discovery projects with an 86% success rate as of Q3 2024, scientific advisory board members with combined delivery of 8 new chemical entities to clinic, and named collaborations with Ono Pharmaceutical, Sareum Holdings, BriaCell Therapeutics, PRISM BioLab, and Lubrizol.
RECEPTOR.AI firmographics
Firmographics- Name
- RECEPTOR.AI
- Legal name
- Receptor.ai Inc.
- Website
- https://receptor.ai
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Receptor.AI is a TechBio company offering an AI-native multiplatform drug discovery ecosystem spanning small molecules, peptides, and induced proximity modalities. It serves pharmaceutical, biotechnology, and academic clients globally through project-based services and SaaS access, supported by proprietary QuorumMap, ArtiDock, and ADMETiQ AI models.
- Ownership category
- akta.pro rank
RECEPTOR.AI industry classification
Industry- Product category
- AI Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)
- SIC
- Services-Computer Integrated Systems Design (7373)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
Keywords
Where RECEPTOR.AI is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
RECEPTOR.AI business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Collaborative Drug Discovery Services: Revenue generated through collaborative research partnerships with pharmaceutical companies. Projects span hit identification, hit-to-lead, lead optimization, and preclinical candidate selection. Services are provided on a project basis with direct scientific team engagement.
- Platform Access and Technology Licensing: Access to AI-powered drug discovery platforms including screening workflows, docking tools, and ADMET prediction systems. SaaS platform established for scalable drug discovery solutions.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels8 records
RECEPTOR.AI product offering
Product offeringCore offering
Receptor.AI operates a multiplatform AI ecosystem for preclinical drug discovery spanning three modality-specific platforms — Small Molecules, Peptides, and Biologics & Proximity Inducers. The platforms integrate proprietary AI models including QuorumMap (chemical space navigation), ArtiDock (AI docking), ADMETiQ (ADMET prediction), and Oracle.AI (virtual screening) to support hit identification, lead optimization, and preclinical candidate selection. The company delivers these capabilities through collaborative drug discovery partnerships and SaaS platform access for pharmaceutical and biotech organizations.
Product overview
Receptor.AI is a TechBio company offering a multiplatform AI ecosystem for preclinical drug discovery across three modality-specific platforms: Small Molecules, Peptides, and Biologics & Proximity Inducers. The modular architecture provides end-to-end drug candidate design capabilities within each platform, orchestrated by Agentic AI systems. Core technologies include QuorumMap for chemical space navigation, ArtiDock for AI-powered protein-ligand docking, ADMETiQ for predictive ADMET evaluation, and Oracle.AI for virtual screening. The platforms are seamlessly integrated with specialized experimental laboratories providing validated workflows from hit identification through lead optimization.
Differentiator
Problem solved
Functional benefit
Products and services
- Small Molecule Platform AI-driven drug discovery platform for de novo design of small molecules targeting kinases, GPCRs, ion channels, enzymes, and other protein classes. Includes AI pocket identification (allosteric, hidden, transient, cryptic), automated SAR analysis, multiparametric virtual screening with QuorumMap, selectivity optimization, and ADMET prediction across 80+ endpoints. Used by pharma and biotech discovery teams.
- Peptide Platform AI-guided de novo design and optimization of linear and cyclic peptides for challenging targets including undruggable protein-protein interactions. Features a library of 10K+ non-canonical amino acids, non-peptide blocks, and linkage chemistry with multiparametric optimization for activity, permeability, and oral availability. Used by pharma and biotech drug discovery teams.
- Biologics & Proximity Inducers Platform Platform for designing proximity inducers such as degraders, molecular glues, and PPI disruptors. Enables antibody-based therapeutics including bispecifics, immune cell engagers, and antibody-guided scaffolds. Predicts PPI structures and ternary complexes for both natural and induced PPIs. Targets protein-protein interactions and complex receptor systems.
- QuorumMap AI-guided navigation system for exploring 10^16-scale chemical space in information-rich batches. Combines multiple docking engines and ADMET models with a multi-parameter reward function that prioritizes compounds by docking quality, ADMET properties, selectivity, drug-likeness, novelty, and diversity. Uses uncertainty + diversity strategy for batch selection.
- ArtiDock Best-in-class AI docking model that outperforms all conventional and AI docking techniques including AlphaFold. Used for ensemble AI docking with target-specific rescoring. Ranked as the world's top-performing molecular docking model.
- ADMETiQ Predictive system for ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) evaluation covering 80+ parameters. Includes dedicated BBB (blood-brain barrier) model for predicting CNS permeability. Integrated into optimization workflows for lead compound refinement.
- Oracle.AI Virtual screening platform combining AI models including ArtiDock with physics-based approaches for identifying promising drug candidates. Uses ensemble docking and knowledge graph analysis for compound prioritization.
- Collaborative Drug Discovery Services Project-based collaborative drug discovery services spanning hit identification, hit-to-lead, lead optimization, and preclinical candidate selection. Delivered through direct scientific team engagement with pharmaceutical and biotech partners on a quote-based enterprise model.
Quantifiable outcome
- 86% project success rate for completed drug discovery projects
- +7 more outcomes
Companies that use RECEPTOR.AI
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles4 records
RECEPTOR.AI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature8 records
RECEPTOR.AI partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- PRISM BioLabcoreDrug discovery collaboration to develop an integrated AI-navigated platform for discovering orally available small molecules targeting protein-protein interactions, membrane proteins, and complex receptor systems. Combines PRISM's PepMetics chemistry with Receptor.AI's AI navigation engine, initially focusing on metabolic diseases including obesity. Both companies aim to jointly engage pharmaceutical partners.
- BriaCell Therapeutics Corp.coreCollaboration on AI-driven small molecule cancer therapeutics. BriaCell focuses on developing immunotherapies and personalized treatments for cancer with Phase 3 lead candidate Bria-IMT.
- LubrizolminorCollaboration launched Q3 2025 to advance AI-guided peptide innovation for skin care and bioactive peptide discovery.
- Sareum Holdings plccoreStrategic collaboration for discovery and optimization of blood-brain barrier (BBB)-permeable, isoform-selective TYK2/JAK1 inhibitors for neuroinflammatory conditions including multiple sclerosis and Parkinson's disease. Receptor.AI uses Oracle.AI virtual screening platform with ArtiDock and physics-based approaches. Sareum retains ownership of resulting IP.
- Ono Pharmaceutical (小野薬品工業)coreResearch collaboration launched Q1 2025 to design novel therapeutics, strengthening Receptor.AI's reach in the Japanese pharma market. Ono is a leader in Japan's innovation ecosystem.
- Peptide Drug Hunting Consortium (PDHC)minorBecame member of PDHC contributing AI expertise and joining advisory boards. Collaborative initiative for peptide drug discovery.
- Major Pharmaceutical Company (Membrane Mitochondrial Kinases)coreKey partnership established Q1 2024 with major pharmaceutical company concentrating on membrane mitochondrial kinases.
- NvidiacorePartnership with Nvidia to enhance generative AI capabilities for drug discovery platform development.
Scale indicators9 records
Recent moves9 records
Expansion highlights7 records
RECEPTOR.AI competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key highlights7 records
Customer concentration
RECEPTOR.AI social profiles
Digital presenceRECEPTOR.AI financial estimates
Financial estimateRevenue estimate
Valuation estimate
RECEPTOR.AI leadership team
Management profileNumber of profiles
Profiles13 records
RECEPTOR.AI funding detail
Funding detailFunding overview
Funding rounds3 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RECEPTOR.AI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RECEPTOR.AI
What does RECEPTOR.AI do?
Receptor.AI operates a multiplatform AI ecosystem for preclinical drug discovery spanning three modality-specific platforms — Small Molecules, Peptides, and Biologics & Proximity Inducers. The platforms integrate proprietary AI models including QuorumMap (chemical space navigation), ArtiDock (AI docking), ADMETiQ (ADMET prediction), and Oracle.AI (virtual screening) to support hit identification, lead optimization, and preclinical candidate selection. The company delivers these capabilities through collaborative drug discovery partnerships and SaaS platform access for pharmaceutical and biotech organizations.
Is RECEPTOR.AI a public or private company?
RECEPTOR.AI is a private company. It is classified as venture growth investor backed and is currently operating.
When was RECEPTOR.AI founded?
RECEPTOR.AI was founded in 2021. It employs 51 to 100 people.
Where is RECEPTOR.AI based?
RECEPTOR.AI is headquartered in Cambridge, United States, in the North America region.
How does RECEPTOR.AI make money?
Two revenue lines are on record. Collaborative Drug Discovery Services are the primary driver. The others are platform Access and Technology Licensing.
Does RECEPTOR.AI have an API?
No public API is recorded for RECEPTOR.AI.
What industry is RECEPTOR.AI in?
RECEPTOR.AI's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 7373.